Endocrinology · Metabolic Bone Disease
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Primary hyperparathyroidism is the most common cause of hypercalcemia in the outpatient setting, typically presenting with an elevated PTH level.
Malignancy is the most common cause of hypercalcemia in the inpatient setting, often driven by PTHrP secretion in squamous cell carcinoma.
Corrected calcium must be calculated in patients with hypoalbuminemia using the formula: measured calcium + 0.8 * (4.0 - serum albumin).
Shortened QT interval on electrocardiogram is a classic cardiac manifestation of severe hypercalcemia.
Aggressive intravenous hydration with normal saline is the first-line treatment for symptomatic hypercalcemia to restore intravascular volume and promote calciuresis.
Denosumab is suggested in preference to an IV bisphosphonate (e.g., zoledronic acid) as first-line antiresorptive therapy for hypercalcemia of malignancy; bisphosphonates begin lowering calcium in 2-4 days, with the maximal effect nearer 4-7 days.
Familial hypocalciuric hypercalcemia (FHH) is characterized by a benign clinical course, low urinary calcium excretion, and a calcium-sensing receptor mutation.
Vignette unlocked
A 62-year-old male presents to the emergency department with lethargy, constipation, and polyuria. He has a history of smoking and recent unintentional weight loss. Physical examination reveals dry mucous membranes and decreased deep tendon reflexes. Laboratory studies show a serum calcium of 13.8 mg/dL, suppressed PTH, and an elevated PTHrP level.
What is the most appropriate initial management for this patient's condition?
Aggressive intravenous normal saline hydration
The patient presents with symptomatic hypercalcemia of malignancy; the first-line management for all symptomatic hypercalcemia is volume expansion with intravenous fluids to restore renal perfusion and promote calcium excretion.
Full handout
High yield triage
Etiology / Epidemiology
Primary hyperparathyroidism (outpatient) and malignancy (inpatient) account for 90% of cases.
Clinical Manifestations
Classic stones, bones, abdominal groans, and psychiatric overtones; shortened QT interval on EKG.
Diagnosis
Confirm with ionized calcium; elevated PTH distinguishes primary hyperparathyroidism from malignancy.
Treatment
First-line is IV normal saline for volume expansion; denosumab is now suggested first-line over an IV bisphosphonate for malignancy-associated cases.
Prognosis
Severe hypercalcemia (>14 mg/dL) is a medical emergency requiring aggressive hydration plus calcitonin, which is stopped after 48-72 hours because of tachyphylaxis, combined with either denosumab or an IV bisphosphonate.
Full handout
Epidemiology & Etiology
Primary hyperparathyroidism is the most common cause in asymptomatic patients, often due to a solitary adenoma. Malignancy (via PTHrP secretion or bone metastasis) is the most common cause in hospitalized patients. Other causes include thiazide diuretics, lithium, and granulomatous diseases like sarcoidosis.
Pertinent Anatomy
The parathyroid glands regulate calcium via PTH secretion. PTH acts on the distal convoluted tubule to increase calcium reabsorption and on bone to stimulate osteoclast activity. The kidneys are the primary site of regulated calcium excretion, although on a typical intake most unabsorbed calcium leaves the body in stool.
Pathophysiology
Elevated PTH increases serum calcium by stimulating bone resorption and renal calcium reabsorption. In malignancy, PTHrP mimics PTH, leading to hypercalcemia without elevated PTH levels. Chronic hypercalcemia leads to nephrocalcinosis and impaired renal concentrating ability, causing polyuria and volume depletion.
Clinical Manifestations
Patients present with stones (nephrolithiasis), bones (bone pain/fractures), abdominal groans (constipation/pancreatitis), and psychiatric overtones (confusion/depression). EKG findings include a shortened QT interval and arrhythmias. Severe cases present with lethargy, coma, and cardiac arrest.
Diagnosis
Total calcium is conventionally adjusted for albumin using corrected Ca = serum Ca + 0.8(4.0 - serum albumin), but this adjustment performs poorly in critical illness, CKD, and marked hypoalbuminemia and should not substitute for a measured ionized calcium when the result drives management. The ionized calcium level is the gold standard for true hypercalcemia. An elevated or inappropriately normal PTH level indicates PTH-dependent hypercalcemia; confirm primary hyperparathyroidism by excluding familial hypocalciuric hypercalcemia with a 24-hour urine calcium and calcium-to-creatinine clearance ratio (<0.01 in FHH), while a suppressed PTH suggests malignancy or other non-PTH mediated causes.
Treatment
Initial management is IV normal saline to restore volume and promote calciuresis. Calcitonin gives rapid but transient lowering within hours, while denosumab is suggested in preference to an IV bisphosphonate (e.g., zoledronic acid) as first-line antiresorptive therapy for malignancy-associated hypercalcemia; when denosumab is given in advanced CKD, calcium must be monitored closely because of the risk of severe hypocalcemia. Loop diuretics are not recommended as a routine calciuretic measure and are reserved for patients who develop volume overload during saline hydration.
Prognosis
Hypercalcemia >14 mg/dL is a life-threatening emergency requiring immediate intervention. Long-term complications include nephrolithiasis, chronic kidney disease, and pathologic fractures. Patients require serial monitoring of serum calcium and renal function.
Differential Diagnosis
Primary Hyperparathyroidism: Elevated PTH and elevated calcium
Malignancy: Suppressed PTH and elevated PTHrP
Sarcoidosis: Elevated 1,25-dihydroxyvitamin D
Thiazide use: Mild hypercalcemia, resolves after discontinuation
Familial Hypocalciuric Hypercalcemia: Low urinary calcium excretion